Caxton Corp added to its Strongbridge Bio stake. The biopharma stock is Bruce Kovner’s #2 position.

21_Bruce Kovner

Many traders know of Bruce Kovner, the cab driver turned multi-billionaire, from his interview with Jack Schwager in the classic investment book Market Wizards. As founder and Chairman of Caxton Associates from 1983 to 2011, Kovner reportedly averaged 21% annual returns. Kovner managed as much as $14 billion in global macro strategies. So when Kovner’s family office Caxton Corp added to its Strongbridge Bio stake, it caught my eye.

In a Form 4 filing after market hours yesterday, Caxton disclosed buying 1.48M shares of Strongbridge Biopharma plc (SBBP). The purchases were made at an average price of $2.25. The buying represented a 22% increase in the fund’s previous position.

Caxton Corp files quarterly 13F reports, despite being a private entity. However, Kovner’s family office reported just $94.7M in long stock positions as of Q2. That’s only a fraction of Kovner’s reported $5.3B net worth.

Nonetheless, after Caxton Corp added to its Strongbridge Bio stake, SBBP was the fund’s #2 position. Kovner’s family office holds 8.06M shares of SBBP, making it the stock’s top holder with about a 14.80% position. Kovner’s family office first purchased SBBP shares in June of 2016. The recent buying represented the fund’s first purchases since Dec. of 2018.

Caxton Corp added to its Strongbridge Bio stake, buying $3.3M of shares in a secondary offering.

Strongbridge Biopharma plc is a commercial biotechnology company, founded in 1996, that is focused on developing treatments for rare diseases. SBBP has three drugs in its portfolio, however interest is highest in Recorlev, a drug for the treatment of Endogenous Cushing’s Syndrome. The company estimates that 25,000 patients in the US are currently diagnosed with Cushing’s disease, a rare endocrine disorder characterized by sustained elevated cortisol levels.

On September 9, 2020 SBBP held a conference call to announce positive results of Recorlev’s Phase 3 trial. SBBP management guided investors to expect $250MM-$350MM/year in peak Recorlev sales. This Seeking Alpha analysis concludes that SBBP’s estimate of Recorlev sales “appears very reasonable.” If such revenues are realized, SBBP, with a current market cap of $149MM, looks to be significantly undervalued.

News of Strongbridge Bio’s $25M offering knocked SBBP down over 21% to $2.25. But with investing legend Bruce Kovner’s fund a buyer at that level, the stock may indeed be a bargain.

Strongbridge Biopharma plc (SBBP) one year daily chart. Source: Interactive Brokers


This investment blog (the “Blog”) is created and authored by Mark W. Gaffney (the “Content Creator”). The Blog is provided for informational and entertainment purposes only (collectively, the “Blog Service”). The information in the Blog constitutes the Content Creator’s own opinions. None of the information contained in the Blog constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You understand that the Content Creator is not advising, and will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in the Blog may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

From time to time, the Content Creator or its affiliates may hold positions or other interests in securities mentioned in the Blog. The Content Creator or affiliates may trade for their own account(s) based on the information presented, and may also take positions inconsistent with the views expressed in its messages on the Blog.

The Content Creator may hold licenses with FINRA, the SEC or states securities authorities. These licenses may or may not be disclosed by the Content Creator in the Blog.

Investing in the investments discussed in the Blog may be risky and speculative. The companies may have limited operating histories, little available public information. The stocks discussed may be volatile and illiquid. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital not required for other purposes, such as retirement savings, student loans, mortgages or education.

Full Disclaimer.